Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Zenas BioPharma, Inc. | Director | Stock Option (Right to Buy) | 18.5K | Sep 12, 2024 | Direct | ||
ALEXION PHARMACEUTICALS, INC. | EVP, Research & Development | Common Stock, par value $.0001 per share | 0 | $177.00 | Jul 21, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ZBIO | Zenas BioPharma, Inc. | Sep 12, 2024 | 1 | $0 | 4 | Sep 16, 2024 | Director |
ZBIO | Zenas BioPharma, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | Director |
ALXN | ALEXION PHARMACEUTICALS, INC. | Jul 21, 2021 | 1 | $0 | 4 | Jul 23, 2021 | EVP, Research & Development |
ALXN | ALEXION PHARMACEUTICALS, INC. | Jul 14, 2021 | 2 | $0 | 4 | Jul 16, 2021 | EVP, Research & Development |
ALXN | ALEXION PHARMACEUTICALS, INC. | Jun 8, 2021 | 1 | -$346K | 4 | Jun 9, 2021 | EVP, Research & Development |